ZA200400013B - T cell regulatory genes and methods of use thereof - Google Patents

T cell regulatory genes and methods of use thereof Download PDF

Info

Publication number
ZA200400013B
ZA200400013B ZA200400013A ZA200400013A ZA200400013B ZA 200400013 B ZA200400013 B ZA 200400013B ZA 200400013 A ZA200400013 A ZA 200400013A ZA 200400013 A ZA200400013 A ZA 200400013A ZA 200400013 B ZA200400013 B ZA 200400013B
Authority
ZA
South Africa
Prior art keywords
tim
cells
polypeptide
gene
protein
Prior art date
Application number
ZA200400013A
Other languages
English (en)
Inventor
Jennifer J Mcintire
Rosemarie H Dekruyff
Dale T Umetsu
Gorodn J Freeman
Vijay Kuchroo
Original Assignee
Dana Farber Cancer Institue &
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institue &, Brigham & Womens Hospital filed Critical Dana Farber Cancer Institue &
Publication of ZA200400013B publication Critical patent/ZA200400013B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA200400013A 2001-06-29 2004-01-05 T cell regulatory genes and methods of use thereof ZA200400013B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30234401P 2001-06-29 2001-06-29

Publications (1)

Publication Number Publication Date
ZA200400013B true ZA200400013B (en) 2006-05-31

Family

ID=23167357

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200400013A ZA200400013B (en) 2001-06-29 2004-01-05 T cell regulatory genes and methods of use thereof

Country Status (11)

Country Link
US (2) US7553939B2 (https=)
EP (1) EP1406653A4 (https=)
JP (3) JP4572276B2 (https=)
KR (1) KR20040014997A (https=)
CN (1) CN1538853A (https=)
CA (1) CA2452196A1 (https=)
IL (1) IL159627A0 (https=)
MX (1) MXPA04000034A (https=)
NZ (1) NZ530451A (https=)
WO (1) WO2003002722A2 (https=)
ZA (1) ZA200400013B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044460A1 (en) * 1996-05-24 1997-11-27 Biogen, Inc. Modulators of tissue regeneration
DE60137934D1 (de) * 2000-06-16 2009-04-23 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
EP1401869B1 (en) * 2001-06-01 2007-12-26 Biogen Idec MA Inc. Molecules and methods for inhibiting shedding of kim-1
EP1406653A4 (en) * 2001-06-29 2005-05-04 Univ Leland Stanford Junior T CELL REGULATION GENES AND METHOD OF USE THEREOF
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
AU2003303082B2 (en) * 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
CA2479732A1 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DK1585546T3 (da) * 2002-12-30 2008-12-08 Biogen Idec Inc KIM- 1- Antagonister og Brug til at Modulere Immunsystem
AU2013242840B2 (en) * 2003-03-19 2017-01-19 Amgen Fremont Inc. Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof
DK1613750T3 (en) * 2003-03-19 2016-01-18 Amgen Fremont Inc ANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof
MXPA06003686A (es) * 2003-10-03 2007-03-01 Brigham & Womens Hospital Ligandos tim-3 y sus metodos.
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
AU2005231685A1 (en) * 2004-03-24 2005-10-20 Telos Pharmaceuticals Llc Compositions as adjuvants to improve immune responses to vaccines and methods of use
EP2290071B1 (en) 2004-05-28 2014-12-31 Asuragen, Inc. Methods and compositions involving microRNA
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
CN1778816B (zh) * 2004-11-22 2010-07-07 中国人民解放军第二军医大学 人细胞表面膜分子及用途
EP2251037B1 (en) 2005-03-02 2015-01-14 Biogen Idec MA Inc. KIM-1 antibodies for treatment of TH1/TH2-mediated conditions
KR100746312B1 (ko) * 2005-03-14 2007-08-03 한국화학연구원 수용성 산화철 나노 입자 및 이의 제조방법
WO2008036765A2 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US8071562B2 (en) 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
EP2268832A2 (en) * 2008-03-06 2011-01-05 Asuragen, INC. Microrna markers for recurrence of colorectal cancer
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
WO2010095461A1 (ja) * 2009-02-20 2010-08-26 国立大学法人東京大学 新規モノクローナル抗体、並びにその使用
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
JP6196034B2 (ja) * 2012-12-20 2017-09-13 ライオン株式会社 高血糖リスク判定用マーカーペプチドおよびその用途
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
TWI726920B (zh) * 2015-10-14 2021-05-11 耶魯大學 基因體規模的t細胞活性陣列、其製造方法、其用於辨識免疫調節因子的方法及其用途
IL262365B2 (en) 2016-04-15 2024-11-01 Alpine Immune Sciences Inc Immunomodulatory proteins ICOS ligand variants and uses thereof
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
MY200602A (en) 2016-07-14 2024-01-04 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
US11203637B2 (en) * 2016-08-26 2021-12-21 Beigene, Ltd. Anti-Tim-3 antibodies and use thereof
EP4089116A1 (en) 2016-09-27 2022-11-16 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
WO2018086594A1 (en) 2016-11-11 2018-05-17 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tim-3
BR112019020959A2 (pt) * 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
EP3688032B1 (en) 2017-09-26 2025-11-05 Cero Therapeutics Holdings, Inc. Chimeric engulfment receptor molecules and methods of use
CN108037292A (zh) * 2017-11-29 2018-05-15 天津市湖滨盘古基因科学发展有限公司 一种人的磷脂酰丝氨酸受体突变蛋白及其应用
WO2019191334A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
JP7444781B2 (ja) 2018-03-28 2024-03-06 セロ・セラピューティクス・インコーポレイテッド 細胞免疫療法組成物およびその使用
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
CN110412263B (zh) * 2019-07-31 2023-01-31 中国农业科学院茶叶研究所 一种快速高效的茶树质体型谷氨酰胺合成酶基因定位方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1997044460A1 (en) * 1996-05-24 1997-11-27 Biogen, Inc. Modulators of tissue regeneration
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US7060458B1 (en) * 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
CA2319129A1 (en) * 1998-01-30 1999-08-05 Human Genome Sciences, Inc. 67 human secreted proteins
CA2324648C (en) * 1998-03-27 2013-02-26 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
WO2002081517A2 (en) * 2001-01-19 2002-10-17 Curagen Corporation Novel polypeptides and nucleic acids encoded thereby
EP1406653A4 (en) * 2001-06-29 2005-05-04 Univ Leland Stanford Junior T CELL REGULATION GENES AND METHOD OF USE THEREOF

Also Published As

Publication number Publication date
MXPA04000034A (es) 2005-11-23
JP2007000146A (ja) 2007-01-11
JP2010057492A (ja) 2010-03-18
JP4351233B2 (ja) 2009-10-28
JP2005500039A (ja) 2005-01-06
EP1406653A2 (en) 2004-04-14
CN1538853A (zh) 2004-10-20
CA2452196A1 (en) 2003-01-09
US20090252737A1 (en) 2009-10-08
KR20040014997A (ko) 2004-02-18
IL159627A0 (en) 2004-06-01
JP4572276B2 (ja) 2010-11-04
WO2003002722A3 (en) 2003-04-03
EP1406653A4 (en) 2005-05-04
WO2003002722A2 (en) 2003-01-09
NZ530451A (en) 2008-04-30
WO2003002722A9 (en) 2004-04-15
US20030124114A1 (en) 2003-07-03
US7553939B2 (en) 2009-06-30

Similar Documents

Publication Publication Date Title
US7553939B2 (en) T cell regulatory genes and methods of use thereof
US9683049B2 (en) Modulation of TIM receptor activity in combination with cytoreductive therapy
US7838220B2 (en) T cell regulatory genes associated with immune disease
Yawata et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function
Mengle-Gaw et al. Genetics and expression of mouse Ia antigens.
Schimenti et al. A candidate gene family for the mouse t complex responder (Tcr) locus responsible for haploid effects on sperm function
US8288096B2 (en) Diagnostic method for epilepsy
JP2003529315A (ja) 病気の診断および治療のための成分および方法
EP1852505B1 (en) Mutations in ion channels
US7282336B2 (en) Method of diagnosing epilepsy
Shakhov et al. SPLASH (PLA2IID), a novel member of phospholipase A2 family, is associated with lymphotoxin deficiency
AU2002318462A1 (en) T cell regulatory genes and methods of use thereof
WO2005118854A1 (en) Fcgr3a gebotype and methods for evaluating treatment response to non-depleting antibodies
US7709225B2 (en) Nucleic acids encoding mutations in sodium channels related to epilepsy
US20040214990A1 (en) Transmembrane protein differentially expressed in cancer
US6803184B1 (en) MPR-related ABC transporter encoding nucleic acids and methods of use thereof
US20040242468A1 (en) Gene involved in mineral deposition and uses thereof
DeVoe Leveraging Natural Genetic Variation to Fine Map CD8 T Cell Exhaustion-Associated Regulatory Elements
HK1069996A (en) T cell regulatory genes and methods of use thereof